


a.) Amendment to the Claims:


1. (Original) A pharmaceutical composition which comprises (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



or a pharmaceutically acceptable salt thereof, and

(b) an α_1 -adrenoceptor antagonist.

2. (Original) The pharmaceutical composition according to Claim 1, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(1a)

3. (Currently Amended) The pharmaceutical composition according to Claim 1 or 2, wherein the α_1 -adrenoceptor antagonist ~~is/are selected from any one of or more than~~ is at least one of the following: group consisting of tamsulosin, prazosin, terazosin, urapidil, doxazosin, alfzosin, naftopidil, maftopidil, abanoxil and indolamin, and pharmaceutically acceptable salts thereof.

Claims 4-6 (Cancelled).

7. (Currently Amended) A kit which comprises (a) a first component containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and

(b) a second component containing ~~an~~ at least one α_1 -adrenoceptor antagonist.

8. (Original) The kit according to Claim 7, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

9. (Currently Amended) The kit according to Claim 7 or 8, wherein the α_1 -adrenoceptor antagonist ~~is/are selected from any one of or more than~~ is at least one of the following: group consisting of tamsulosin, prazosin, terazosin, urapidil, doxazosin, alfzozin, naftopidil, maftopidil, abanoxil and indolamin, and pharmaceutically acceptable salts thereof.


Claims 10-12 (Cancelled).

13. (Currently Amended) 3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




or a pharmaceutically acceptable salt thereof, ~~which may be administered together or separately at an interval with an α_1 -adrenoceptor antagonist.~~

14. (Original) 3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof according to Claim 13, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



Claim 15 (Cancelled).


16. (Currently Amended) A pharmaceutical composition which comprises, as an active ingredient, 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, ~~which may be administered together or separately at an interval with an α_1 -adrenoceptor antagonist~~ together with a pharmaceutically acceptable carrier.


17. (Original) The pharmaceutical composition according to Claim 16, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)

18. (Currently Amended) The pharmaceutical composition according to Claim 16 or 17, ~~wherein the~~ further comprising at least one α_1 -adrenoceptor antagonist ~~is/are selected from any one of or more than one of the following:~~ selected from the group consisting of tamsulosin, prazosin, terazosin, urapidil, doxazosin, alfzosin, naftopidil, maftopidil, abanoxil and indolamin, and pharmaceutically acceptable salts thereof.

19. (Currently Amended) A method for treating bladder irritative symptoms accompanied by benign prostatic hyperplasia, which comprises administering (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and (b) an α_1 -adrenoceptor antagonist, which said (a) and (b) may be administered together or separately at an interval.

20. (Original) The method for treating bladder irritative symptoms accompanied by benign prostatic hyperplasia according to Claim 19, wherein 3,3,3-

trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)

21. The method for treating bladder irritative symptoms accompanied by benign prostatic hyperplasia according to Claim 19 or 20, wherein the α_1 -adrenoceptor antagonist ~~is/are selected from any one of or more than one of the following:~~ is at least one member selected from the group consisting of tamsulosin, prazosin, terazosin, urapidil, doxazosin, alfzosin, naftopidil, maftopidil, abanoxil and indolamin, and pharmaceutically acceptable salts thereof.

22. (New) The method for treating overactive bladder according to Claims 19 or 20, comprising administering plural α_1 -adrenoceptor antagonists separately or at an interval.